For the quarter ending 2026-03-31, AARD had $15,385K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -21,588 | -17,598 | -16,316 | -23,677 |
| Credit loss - related party accounts receivable | - | 0 | 0 | 0 |
| Stock-based compensation expense | 2,004 | 1,581 | 1,500 | 867 |
| Non-cash lease expense | 86 | 84 | 83 | 213 |
| Unrealized loss on short-term investments | -13 | -19 | 36 | -22 |
| Amortization of discount on short-term investments | 118 | 233 | 372 | 701 |
| Depreciation expense | 11 | 10 | 10 | 16 |
| Prepaid expenses and other assets | 333 | 369 | 1,313 | 4,278 |
| Accounts payable | 2,421 | -2,372 | -612 | 3,223 |
| Accrued liabilities | -1,260 | 2,172 | 1,026 | 3,217 |
| Operating lease liability | -105 | -104 | -100 | -134 |
| Net cash used in operating activities | -18,869 | -16,810 | -16,130 | -21,232 |
| Purchases of short-term investments | 0 | 4,948 | 0 | 124,651 |
| Maturities/sales of short-term investments | 34,250 | 29,250 | 29,250 | 21,527 |
| Purchases of property and equipment | - | 0 | 4 | 91 |
| Proceeds from sale and issuance of series c convertible preferred stock | - | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | 34,250 | 24,302 | 29,246 | -103,215 |
| Proceeds from sale and issuance of common stock in initial public offering, net of underwriting discounts | 0 | 0 | 0 | 91,075 |
| Financing costs paid in connection with initial public offering | 0 | 0 | 0 | 2,387 |
| Financing costs paid in connection with issuance of series c convertible preferred stock | - | 0 | 0 | 0 |
| Proceeds from exercises of common stock options | 4 | 79 | 171 | 116 |
| Proceeds from issuance of common stock under employee stock purchase plan | - | 195 | - | - |
| Costs paid in connection with deferred financing costs | - | 0 | - | - |
| Net cash provided by financing activities | 4 | 274 | 171 | 88,804 |
| Net increase (decrease) in cash and cash equivalents | 15,385 | 7,766 | 13,287 | -35,643 |
| Cash and cash equivalents at beginning of year | 47,051 | 39,285 | 61,641 | - |
| Cash and cash equivalents at end of year | 62,436 | 47,051 | 39,285 | - |
Aardvark Therapeutics, Inc. (AARD)
Aardvark Therapeutics, Inc. (AARD)